HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

setrusumab

targets sclerostin

Also Known As:

BPS-804; BPS804; MOR05813

Networked: 3 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        setrusumab: 3
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        setrusumab: 3
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        setrusumab: 3

Experts

1.	Hemsley, Sarah: 2 articles (07/2017 - 06/2017)
2.	Jakob, Franz: 2 articles (07/2017 - 06/2017)
3.	Junker, Uwe: 2 articles (07/2017 - 06/2017)
4.	Seefried, Lothar: 2 articles (07/2017 - 06/2017)
5.	Katoh, Masaru: 1 article (09/2017)
6.	Katoh, Masuko: 1 article (09/2017)
7.	Devogelaer, Jean-Pierre: 1 article (07/2017)
8.	Durigova, Michaela: 1 article (07/2017)
9.	Glorieux, Francis H: 1 article (07/2017)
10.	Goemaere, Stefan: 1 article (07/2017)

Related Diseases

1.	Hypophosphatasia 06/01/2017 - "Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia."
2.	Osteogenesis Imperfecta (Lobstein Disease) 07/01/2017 - "This 21-week, open-label, phase 2a trial aimed to evaluate the pharmacodynamics and safety of multiple, escalating infusions of BPS804, a neutralizing, anti-sclerostin antibody, in adults with moderate osteogenesis imperfecta (OI). " 07/01/2017 - "BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial."
3.	Neoplasms (Cancer) 09/01/2017 - "By contrast, Dickkopf-related protein 1 (DKK1), SOST and glycogen synthase kinase 3β (GSK3β) are targets of pro-WNT signaling therapy, and anti-DKK1 (BHQ880 and DKN-01) and anti-SOST (blosozumab, BPS804 and romosozumab) monoclonal antibodies are being tested in clinical trials for cancer patients and osteoporotic post-menopausal women. "
4.	Bone Resorption 07/01/2017 - "BPS804 stimulates bone formation, reduces bone resorption, and increases lumbar spine aBMD in adults with moderate OI. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Glycogen Synthase (Synthase I)
3.	BHQ880
4.	romosozumab
5.	blosozumab

Related Therapies and Procedures

1.	Therapeutics